Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Lung Cancer Analytical Tool Report 2016 - 553 Companies Plus Partners who are Today Developing 1130 Lung Cancer Drugs - Research and Markets

Research and Markets
Posted on: 19 Sep 16

Research and Markets has announced the addition of the "Lung Cancer: Analytical Tool" report to their offering.

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals from a business development, drug development or investment perspective.

It covers more than 553 companies plus partners who are today developing 1130 lung cancer drugs where of 809 are active in 884 developmental projects in cancer across 435 different targets. The Analytical Tool and its contents are yours to keep and data can be easily exported into Excel format for mixing with your own proprietary information.

The Analytical Tools have proven their worth to our clients in oncology for almost two decades in their capacities covering:

  • Target Scouting
  • Early & Late Stage Pipeline Analysis
  • Biomarker/Companion Diagnostic Analysis
  • Deal & Alliance Analysis
  • Combination Therapy Analysis
  • Indication Selection & Expansion Analysis
  • First-in-Class Analysis
  • Drug Repositioning
  • Pipeline Analysis by Targeted Pathways

For more information about this report visit

Related Topics: Lung Cancer Drugs

View source version on

Business Wire

Last updated on: 19/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.